BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cardiovascular BioTherapeutics, Inc. (CVBT.OB) Interim Board of Directors Remains in Place


6/24/2013 9:46:37 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAS VEGAS, June 21, 2013 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (CVBT) announced today that the Delaware Court of Chancery ruled that Mickael A. Flaa, Grant Gordon, Calvin A. Wallen III, Jon Ross, and Robert Schleizer will remain in place as the CVBT Board of Directors pending resolution of the lawsuit filed on June 9, 2013, by Mickael A. Flaa in that Court. The Delaware lawsuit seeks, among other things, to confirm the validity of the action by written consent of stockholders on June 7, 2013, to remove Daniel C. Montano, John (Jack) Jacobs, Ernest C. Montano, Viktoriya T. Montano, Ernest Montano III, and Joong Ki Baik as directors of CVBT. Pending resolution of the Delaware lawsuit, or further order of the Delaware Court of Chancery, the power of CVBT's interim Board of Directors to take certain [extraordinary] actions on behalf of CVBT will be limited by a status quo order, which has not yet been entered.

About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to tissue or organs. The company is the sponsor of a Phase II trial to treat severe coronary heart disease (CVBT-141H), and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A Late-Stage trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contacts:
Allison Caplan
CardioVascular BioTherapeutics, Inc.
(702) 839-7200
acaplan.cvbt@gmail.com

CVBT Mailing List
To be added to the CVBT Mailing List, please send your contact information to info@cvbtshareholder.com.

SOURCE CardioVascular BioTherapeutics, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES